Related Experiment Videos

Management and Outcomes Among Chinese Hospitalized Patients With Established Cardiovascular Disease or Multiple Risk

Jingang Yang1, Yuejin Yang2, Hongqiu Gu2

  • 1State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China jingangyang@126.com.

Angiology
|April 30, 2015
PubMed

Insights

Hospitalized patients with peripheral artery disease (PAD) face higher cardiovascular death risks. Increased affected arterial beds significantly elevate cardiovascular event rates in patients with atherosclerotic arterial disease.

Area of Science:

  • Cardiovascular Medicine
  • Atherothrombosis Research
  • Public Health

Background:

  • Hospitalized patients with cardiovascular (CV) diseases or multiple risk factors (MRFs) represent a significant clinical challenge.
  • Atherothrombosis, encompassing coronary artery disease (CAD), stroke, and peripheral artery disease (PAD), affects multiple vascular beds and increases morbidity and mortality.
  • Understanding management and outcomes across different CV conditions is crucial for optimizing patient care.

Purpose of the Study:

  • To assess the management and outcomes of hospitalized patients with established atherothrombotic diseases or multiple risk factors.
  • To compare cardiovascular death rates and atherothrombotic events among patients with CAD, stroke, PAD, or MRFs.
  • To investigate the impact of the number of affected arterial beds on cardiovascular outcomes.

Main Methods:

  • Retrospective study of 3732 hospitalized patients from October 2004 to January 2005.
  • Patients were categorized by CV disease (CAD, stroke, PAD) or multiple risk factors (MRFs).
  • Outcomes analyzed included cardiovascular death, myocardial infarction (MI), stroke, and hospitalization for atherothrombotic events.

Main Results:

  • Patients with PAD had higher CV mortality (5.1%) compared to CAD (3.73%) and stroke (4.1%) patients.
  • Cardiovascular death increased with the number of affected arterial beds, ranging from 1.2% (MRFs) to 6.4% (3-bed disease).
  • Medication use, particularly statins and antiplatelet agents, varied, with lowest use observed in the PAD-only group.

Conclusions:

  • Peripheral artery disease (PAD) is associated with a particularly high risk of cardiovascular death among hospitalized patients.
  • The number of affected arterial beds is a significant predictor of adverse cardiovascular events.
  • Intensified management and targeted therapies are warranted for patients with multi-vascular bed involvement and PAD to reduce atherothrombotic risk.

Keywords:
atherosclerosisatherothrombosiscoronary artery diseaseperipheral artery diseasestroke

Related Concept Videos

Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
490
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
866
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
702
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
603
Cardiomyopathy VI: Nursing Management01:29

Cardiomyopathy VI: Nursing Management

Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
471
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
775